Adagene (NASDAQ:ADAG) specializes in antibody discovery and engineering, focusing on developing innovative solutions for cancer immunotherapy. This company leverages its proprietary Dynamic Precision Library and SAFEbody technologies to create a robust pipeline of clinical and preclinical candidates aimed at addressing unmet medical needs in oncology. Adagene's projects revolve around advancing these candidates through rigorous clinical trials, with the objective of introducing more effective, less toxic cancer therapies. The company's operations span across research and development, clinical trial management, and strategic partnerships to speed up the delivery of their innovative treatments to patients worldwide. Adagene's mission is to transform the landscape of cancer treatment by advancing the frontiers of antibody engineering and immunotherapy.